

College of Physicians
212-326-5720 (Te

Owen A. O'Connor M.D., Ph.D. Director,
Center for Lymphoid Malignancies
51 West 51st Street; Suite 200
New York, NY 10019
212-326-5720 (Tel)
212-326-5725 (Fax)

August 12, 2015

Ms. Dorothy Graham President Graham Family Foundation 544 61st Street Oakland, CA 94609

Dear Ms. Graham,


I hope this letter finds you well and enjoying the summer. It was wonderful to see you in June. Thank you again for taking the time to visit us.

We are most grateful for your contribution of \$75,000, which is the second installment of the Graham Family Foundation's grant of \$100,000 to the Lymphoid Malignancy Research Fund at Columbia University Medical Center (CUMC).

This contribution will support clinical and translational research efforts in the area of Hodkin's Lymphoma, with the ultimate goal of developing novel therapies toward a cure for this disease.

The funds will be used during Columbia's fiscal year 2016 (beginning July 1, 2015 and ending June 30, 2016). Below is a summary of how we anticipate using the funds. A detailed report on how the funds from the second installment grant have been used will be provided to you in July 2016.

Summary of Anticipated Gift Expenditures	
Gift Beginning Balance	\$75,000
Laboratory Research	
Laboratory Supplies & Materials	\$15,000
Animal Care	\$6,750
Laboratory Services	\$6,750
Laboratory Space and Operations	\$9,000
Total Laboratory Research	\$37,500
Clinical Research	
Routine Clinical Services	\$16,500
Clinical Supplies and Materials	\$6,000
Clinical Space and Operations	\$15,000
Total Clinical Research	\$37,500



College of Physicians and Surgeons

Owen A. O'Connor M.D., Ph.D. Director, Center for Lymphoid Malignancies 51 West 51st Street; Suite 200 New York, NY 10019 212-326-5720 (Tel) 212-326-5725 (Fax)

Your ongoing and generous support of the Center for Lymphoid Malignancies will continue having significant impact on how we are able to help speed the progress of critical, and often underfunded, medical research. The faster we can understand lymphoma and other hematological cancers at their most fundamental levels, the more rapidly we can develop new treatments and improve outcomes for patients who suffer from these complex and challenging diseases.

Again, thank you for your investment and continued partnership. I look forward to staying in touch and providing you with information about the Center's advances in blood diseases research and treatment.

Warmest regards,

Owen A. O'Connor, M.D., Ph.D.

Professor of Medicine and Experimental Therapeutics

Director, Center for Lymphoid Malignancies